COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) for which Priority is Claimed:

EP-Application, 00128477.7 of December 23, 2000

And I hereby appoint

Douglas B. Henderson, Reg.No. 20,291; Arthur S. Garrett, Reg.No. 20,338

Jerry D. Voight, Reg.No. 23,020; Herbert H. Mintz, Reg.No. 26,691;

Thomas L. Irving, Reg.No. 28,619; Thomas W. Winland, Reg.No. 27,605;

Martin I. Fuchs, Reg.No. 28,805; Susan H. Griffen, Reg.No. 30,907;

Richard B. Racine, Req.No. 30,415; Thomas H. Jenkins, Req.No. 30,857;

Carol P. Einaudi, Reg.No. 32,226; Frank E. Caffoe, Reg.No. 18,621;

Allen R. Jensen, Reg.No. 28,224; Bryan C. Diner, Reg.No. 32,409;

M. Paul Barker, Reg.No. 32,013; Charles E. Van Horn, Reg.No. 40,266;

David S. Forman, Reg.No. 33,694;

all of the firm of FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg.No. 22,540, my attorneys, with full power of substitution and revocation to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therein, and specify that communications about the application are to be directed to the following correspondence address:

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER Franklin Square Bldg., Suite 700 1300 | Street, N.W. Washington, DC 20005-3315 Tel. 202-408-4000





I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S) / Residence

1) Dr. Marc Nazaré, Schützenstraße 7, 65817 Eppstein, Germany	
Signature: Mar Whram Date:	Feb 14. 200
2) Dr. David William Will. Kirchstrasse 21, 65830 Kriftel, Germany	y
Signature: David W. Will Date:	18.02.2002
3) Dr. Anuschirwan/Peyman, Zeilsheimer Straße 46, 65779 Kelkh	eim, Germany
Signature: Muschiloau Mus Date:	28.02.2002
4) Dr. Hans Matter, Feldbergring 37, 63505 Langenselbold, Germany	
Signature: Haw Haths Date:	ZZ. OZ. 200Z
5) Dr. Gerhard Zoller, Höhenstraße 8, 61137 Schöneck, Germany	
Signature: 4 Shard for 14.02.2002 Date:	14.02.2002
6) Dr. Uwe Gerlach, Im Heideck 30, 65795 Hattersheim, Germany	
Signature: Mrs file Date:	14.02.2002
The inventors are citizens of 1) Germany 2) United Kingdom 3-6) Germany	•

Post Office Address of all Inventors:

Aventis Pharma Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst, Geb. K 801 65926 Frankfurt am Main, Germany